Study of international cystic fibrosis centers highlights spread of aggressive bacteria

November 10, 2016

A bacterium damaging to the lungs and once thought to be acquired from the environment is actually spread--at least in cystic fibrosis clinics--through human transmission, a new study reveals. The study, which used clinical data from cystic fibrosis centers in Europe, the U.S., and Australia, points to three particularly virulent versions of this bacterium having emerged in recent decades. Mycobacterium abscessus, a species of multidrug resistant mycobacteria, has surfaced as a significant global threat to individuals with cystic fibrosis (CF) and other lung diseases. Previously, it was thought that patients acquired M. abscessus infection from water or soil, and that transmission between patients never occurred. Given the increasing incidence of M. abscessus infections in CF and non-CF populations, however, Josephine Bryant and colleagues sought to better understand whether cross infection, rather than independent environmental acquisition, might be the major infection source. They sequenced whole genomes of over 1,000 versions of M. abscessus from more than 500 individuals attending global CF centers, uncovering near-identical M. abscessus isolates even in different geographies; this suggested the bacterial clones were being widely transmitted within the global CF patient community. Further analysis suggested that the infection may be spread within hospitals via contaminated surfaces and through airborne transmission. How the dominant clones have spread between continents remains unknown, the researchers say; they found no evidence of patients or equipment moving between CF centers in different countries. The study illustrates the power of population-level genomics to uncover modes of transmission of emerging pathogens.

American Association for the Advancement of Science

Related Cystic Fibrosis Articles from Brightsurf:

Treating cystic fibrosis with mRNA therapy or CRISPR
The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation.

Cystic fibrosis: why so many respiratory complications?
Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders.

A newly discovered disease may lead to better treatment of cystic fibrosis
Cystic fibrosis is the most frequent severe inherited disorder worldwide.

New treatment kills off infection that can be deadly to cystic fibrosis patients
The findings, which are published in the journal Scientific Reports, show that scientists from Aston University, Mycobacterial Research Group, combined doses of three antibiotics -- amoxicillin and imipenem-relebactam and found it was 100% effective in killing off the infection which is usually extremely difficult to treat in patients with cystic fibrosis.

Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

Rare mutations drive cystic fibrosis in Caribbean
Cystic Fibrosis (CF) in the Caribbean is dominated by unusual gene mutations not often observed in previously studied CF populations, according to comprehensive genome sequencing led by physician-scientists at UC San Francisco and Centro de Neumología Pediátrica in San Juan.

Cystic fibrosis carriers at increased risk of digestive symptoms
Researchers have found that carriers of the most common genetic variant that causes cystic fibrosis experience some symptoms similar to those of people with cystic fibrosis.

In cystic fibrosis, lungs feed deadly bacteria
A steady supply of its favorite food helps a deadly bacterium thrive in the lungs of people with cystic fibrosis, according to a new study by Columbia researchers.

Cibio knocks out cystic fibrosis
The fight against cystic fibrosis continues, targeting in particular some of the mutations that cause it.

Hypertonic saline may help babies with cystic fibrosis breathe better
Babies with cystic fibrosis may breathe better by inhaling hypertonic saline, according to a randomized controlled trial conducted in Germany and published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Read More: Cystic Fibrosis News and Cystic Fibrosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to